NDATOPICALSWAB
Approved
Jul 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
CLEOCIN (clindamycin phosphate) by Pfizer is clinical pharmacology mechanism of action clindamycin is an antibacterial drug (see). First approved in 1980.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLEOCIN (clindamycin phosphate) is a topical antibacterial agent administered as a vaginal suppository for treatment of bacterial vaginosis and related vaginal infections. It works by inhibiting bacterial protein synthesis, with minimal systemic absorption (approximately 30% on day 3 of dosing). The vaginal formulation delivers substantially lower systemic exposure compared to oral or parenteral clindamycin therapy.
$0.166MPart D
LOE ApproachingDeclining commercial lifecycle with minimal Part D claims (584 in 2023) indicates a mature, commoditized product with limited growth opportunities and likely stable or contracting team size.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Clindamycin is an antibacterial drug (See). Pharmacokinetics Systemic absorption of clindamycin was estimated following a once-a-day intravaginal dose of one clindamycin phosphate vaginal suppository (equivalent to 100 mg clindamycin) administered to 11…
Indications
Worked on CLEOCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.